

GENITOURINARY DISEASE SITE COMMITTEE

CHELSEA HOTEL, TORONTO, ON

ROOM: CHURCHILL BALLROOM B

SATURDAY MAY 4TH, 2024: 10:00 AM – 01:30 PM

CHAIR : SEBASTIEN HOTTE

CO-CHAIRS : TAMIM NIAZI AND WASSIM KASSOUF

SENIOR INVESTIGATORS: MARIAM JAFRI AND WENDY PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- Identify and address, through clinical trial and translational research, the disease burden associated with genitourinary malignancies in Canada.
- Integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct.
- Identify novel agents in the treatments of Genitourinary cancers.
- To provide a learning and mentoring environment supportive to new investigators

08:00 am	GU Workshop: PR.21 - A Randomized Phase II Study of 177Lu-PSMA-617 Vs. Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease Workshop	
09:50 am	Coffee Break	
10:00 am	Main Meeting - Welcome	Sebastien Hotte
10:10 am	Prostate Trials	
	PR.24: ASCENDE-SBRT: Androgen Suppression Combined with Elective Nodal and a Dose Escalated Boost. A Non-Inferiority, Phase 3 Randomized Controlled Trial of Stereotactic Body Radiation Therapy versus Brachytherapy Boost	Joelle Helou
	PR.26 and Update in the Management of Castration-Sensitive Prostate Cancer	Michael Ong
	PR.25 and Update in the Management of Castration-Resistant Prostate Cancer	Michael Kolinsky
	Phase II Randomized Trial of Recurrence-directed therapy (RDT) Without or With Androgen-Deprivation Therapy (ADT) In radio-recurrent oligo-metastatic hormone/Castrate Sensitive Prostate Cancer (romCSPC)	Theos Tsakiridis



11:00am	Renal Trials	
	Practicum and an Update in developments in Renal Cell Carcinoma	Maryam Solemani
	Short TeRm Intensified Pembrolizumab (KEYtruda) and Tivozanib for High-risk renal cell carcinoma -STRIKE (AO32201)	Aly-Khan Lalani
	A randomized trial of ICI-based combination therapy in patients with RCC and recurrence after adjuvant pembrolizumab	Jeffrey Graham
11:40am	Coffee Break	
11:55am	Bladder Trials	
	Guest Lecture: An Update on Recent Trials in Bladder Cancer and Opportunities for Future Research	Thomas Powles
	Q & A	
12:50pm	Active surveillance versus definitive local therapy for patients showing clinical complete response following neoadjuvant treatment, are we ready for a randomized trial?	Marie-Pier St. Laurent
	MODERN (A032103): ctDNA-guided adjuvant bladder trial: MODERN (NCTN)	Guliz Ozgun
	How to improve accrual to Bladder Trials – General Discussion	Sebastien Hotte
1:20pm	Ongoing Trials: Open to Accrual	Mariam Jafri
	GCC1 (S1823): A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours	
	PR.19: A Randomized Phase II Trial Evaluating Treatment Outcome, Acute and Long-term toxicity of High Dose Rate Brachytherapy (HDRB) and Low Dose Rate Brachytherapy (LDRB) as Monotherapy in Localized Prostate Cancer.	
	PR.20: A Randomized Phase III Study of Local Ablative Therapy for Hormone Sensitive Oligometastatic Prostate Cancer (PLATON)	
1:30pm	Closing Remarks	Sebastien Hotte



Ongoing Trials: Closed to Accrual

BLC.1/SWOG S1011: Phase III Surgical Trial to Evaluate the Benefit of Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer

BLC4/SWOG S1605: Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer

PR17/ ANZUP 1304: Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic

REC4/ECOG-ACRIN EA8143: A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

PR.21 PLUDO (Prostate Lutetium/Docetaxel): A Randomized Phase II Study of ¹⁷⁷Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

PR.22: Darolutamide Augments Standard Therapy for Localized High-Risk Cancer of the Prostate (DASL-HiCaP)

